about
Nitric oxide and peroxynitrite in health and diseaseThe endocannabinoid system as an emerging target of pharmacotherapyNeuroanatomical changes in Parkinson's disease in relation to cognition: An updatePathophysiological Role of Peroxynitrite Induced DNA Damage in Human Diseases: A Special Focus on Poly(ADP-ribose) Polymerase (PARP)Possible role of Epoxyeicosatrienoic acid in prevention of oxidative stress mediated neuroinflammation in Parkinson disordersChronic, low-dose rotenone reproduces Lewy neurites found in early stages of Parkinson's disease, reduces mitochondrial movement and slowly kills differentiated SH-SY5Y neural cells.Glial innate immunity generated by non-aggregated alpha-synuclein in mouse: differences between wild-type and Parkinson's disease-linked mutants.Out FOXing Parkinson disease: where development meets neurodegeneration.Microglia acquire distinct activation profiles depending on the degree of alpha-synuclein neuropathology in a rAAV based model of Parkinson's disease.Region-specific protein abundance changes in the brain of MPTP-induced Parkinson's disease mouse modelEffects of Various Flavonoids on the α-Synuclein Fibrillation Process.6-OHDA generated ROS induces DNA damage and p53- and PUMA-dependent cell deathNeuropathology, biochemistry, and biophysics of alpha-synuclein aggregation.Dopamine neurons implanted into people with Parkinson's disease survive without pathology for 14 years.Co-transplantation of GDNF-overexpressing neural stem cells and fetal dopaminergic neurons mitigates motor symptoms in a rat model of Parkinson's diseaseA genome-wide longitudinal transcriptome analysis of the aging model Podospora anserina.Influence of RNA interference on the mitochondrial subcellular localization of alpha-synuclein and on the formation of Lewy body-like inclusions in the cytoplasm of human embryonic kidney 293 cells induced by the overexpression of alpha-synuclein.CD200-CD200R dysfunction exacerbates microglial activation and dopaminergic neurodegeneration in a rat model of Parkinson's diseaseHead injury, α-synuclein Rep1, and Parkinson's disease.Cognitive Impairments in LRRK2-Related Parkinson's Disease: A Study in Chinese Individuals.RNA knockdown as a potential therapeutic strategy in Parkinson's disease.DaT-SPECT assessment depicts dopamine depletion among asymptomatic G2019S LRRK2 mutation carriers.Shedding light into the role of BDNF in the pharmacotherapy of Parkinson's disease.Highbrow proteasome in high-throughput technology.Mechanisms of neuronal death in synucleinopathy.MPP+-induces PUMA- and p53-dependent, but ATF3-independent cell death.Alpha-synuclein and Parkinson's disease: a proteomic view.Decreased vesicular monoamine transporter 2 (VMAT2) and dopamine transporter (DAT) function in knockout mice affects aging of dopaminergic systems.A genome-wide scan in an Amish pedigree with parkinsonism.Transduced Tat-DJ-1 protein protects against oxidative stress-induced SH-SY5Y cell death and Parkinson disease in a mouse model.Functional mechanism of neuroprotection by inhibitors of type B monoamine oxidase in Parkinson's disease.Peripheral biomarkers of Parkinson's disease as early reporters of central neurodegeneration.Aquaporins and neurodegenerative diseases.RNAi: a potential new class of therapeutic for human genetic disease.Rifampicin and Parkinson's disease.Protein interacting with C kinase and neurological disorders.Animal models for drug discovery in dystonia.Mass spectrometric analysis of protein tyrosine nitration in aging and neurodegenerative diseases.Modulation of Neuroinflammation in the Central Nervous System: Role of Chemokines and Sphingolipids.Inhibition of Mitochondrial Clearance and Cu/Zn-SOD Activity Enhance 6-Hydroxydopamine-Induced Neuronal Apoptosis.
P2860
Q24645400-F6AE81CA-DB19-4843-8CE7-A69751A2FDE5Q24648473-5EFAB2BE-966D-416C-941A-434220D45CB3Q28067803-9F88B43F-B3C2-4D8F-9748-881306031F98Q28080057-10B75E82-F0D8-4AD5-8727-B29F57729248Q28386662-20457312-66D0-4AC9-98AA-05B3F67D4BF1Q30440337-6EE93527-0F54-40E1-98A1-C3CFB7CD005CQ30991616-5ACC82AB-DAC9-4A0B-8041-CCDB39989FD4Q33311344-51FD8C12-1539-4CB9-98E1-29221CC89FA5Q33526342-4AB8A2CC-29B6-4B9F-ACE5-DE1B568ACE0DQ33810589-D7AD27CF-D3BE-4D7C-BACF-D2464EA56D5EQ34211735-E6F8BDB1-9360-4478-A3BF-5C7462165106Q34515492-1F88E7BF-AE83-48C0-AF2C-A63CC3F49080Q34648491-F0AE0680-DAC0-431C-BD63-1060AD265721Q34768147-F8D3C0AE-75B5-4186-A250-EC00E3150217Q35061127-5C74A210-8FC1-4549-95A3-300273BFCA83Q35077918-6D277935-3EDC-4C2B-B3E5-B2302122F6BEQ35160746-10787CFB-1E43-49BB-A815-FAA448AA1AB7Q35580088-F399B3C3-B534-4579-BBE3-B9846EC92782Q35726904-A295D50A-4D94-4FE2-B2B0-22FC8818DBD6Q35982596-1E2443BF-5084-4BD3-ACBE-5C9B068F7649Q36305419-1C709E64-0DE5-4BEF-B585-F298DBB0A48DQ36345908-85214BFF-1AD2-4541-9EF9-DDB9A591A165Q36364388-0EDBD0BE-7D20-48B2-A71C-5A4F610A54F3Q36381253-3005D241-3ED1-49A7-80E5-46827AC95F2AQ36626371-7676F269-BCEA-4D8A-B096-E29847525EE4Q36839378-226A3D10-BECF-4E70-BC1E-1C143C7440A0Q37157838-9FFB5375-FE24-4300-82FF-023FE9902118Q37262975-3B004765-F181-45D0-A4E6-8A90576DE9DEQ37392685-88A24E25-EF69-4315-8831-2D3A113E6E67Q37461617-BEAC78AD-7275-4D30-9944-00033AB40A93Q37578490-17F65A94-DC21-4A30-BFC3-09905F758A65Q37755118-FF184A79-5787-40C2-A046-6DB9D1457956Q37814121-34968F8E-E546-457E-BC1F-D774625EFC08Q37871417-D18600A7-51DE-4534-AAD9-D3F7D2576A1CQ38028366-68702141-5718-4015-AECF-3EC7F6CBE60FQ38084249-96572A26-9294-44B1-88DB-7285A2115B9FQ38088284-63ADE67B-43E8-40EC-8266-C48C1902E7E8Q38217025-1DFF1820-E3DC-4A72-94EC-2833DE70D3D9Q38774697-B8E046FC-050F-4BE7-A448-BA6A5E716C80Q38915453-32D99027-A67B-40CD-963E-F7A86BC36A5B
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Molecular pathogenesis of Parkinson disease.
@ast
Molecular pathogenesis of Parkinson disease.
@en
type
label
Molecular pathogenesis of Parkinson disease.
@ast
Molecular pathogenesis of Parkinson disease.
@en
prefLabel
Molecular pathogenesis of Parkinson disease.
@ast
Molecular pathogenesis of Parkinson disease.
@en
P1433
P1476
Molecular pathogenesis of Parkinson disease.
@en
P2093
Jason L Eriksen
P304
P356
10.1001/ARCHNEUR.62.3.353
P577
2005-03-01T00:00:00Z